SCHEMBL4060918

SCHEMBL4060918

c1cc(OC2CCCC2)cc(-c2nc3ccc(-c4ccco4)cc3o2)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 9/20 0.45
ACSL1 P33121 1/20 0.42
NPC1 O15118 5/20 0.41
RAB9A P51151 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 1/20 0.41
CASP3 P42574 1/20 0.41
F2RL3 Q96RI0 2/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
HSP90AA1 P07900 1/20 0.40
KMT2A Q03164 1/20 0.40
FFAR1 O14842 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
MAPT P10636 1/20 0.40
ALOX5 P09917 1/20 0.40
ADORA2A P29274 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4053116 0.82 GPR119 (0.46) GPR119ACSL1NPC1RAB9ASMN1; SMN2
SCHEMBL4057690 0.82 GPR119 (0.55) GPR119RAB9ASMN1; SMN2CASP3KDM4E
SCHEMBL4059615 0.82 RAB9A (0.60) GPR119NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL4061897 0.81 VSIR (0.52) GPR119ACSL1NPC1RAB9ASMN1; SMN2
SCHEMBL4050933 0.81 ALOX5 (0.47) GPR119NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL4054733 0.80 GPR119 (0.43) GPR119ACSL1NPC1RAB9ASMN1; SMN2
SCHEMBL4051901 0.79 NPC1 (0.62) GPR119NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL4050856 0.79 GPR119 (0.55) GPR119NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL4054470 0.79 ADORA1 (0.47) GPR119NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL4052985 0.79 ALDH1A1 (0.60) GPR119NPC1RAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B GPR119 1677/4885ACSL1 2324/4885NPC1 4740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.